A Single and Low Dose of Recombinant Factor VIIa in Patients With Severe Factor XI Deficiency Undergoing Surgery
Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Lately the investigators found that patients with severe factor XI deficiency and inhibitors
could undergo major surgery with a single low dose of recombinant factor VIIa and tranexamic
agent. These results encourage us to apply this treatment in clinical trial setting to
patients with severe factor XI deficiency undergoing surgery instead of blood product.